CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines.

CureVac's stock has been falling Tuesday, down 8.75% to a price of $60.27. The stock's current volume for the day is 709.33 thousand, which is approximately 102.89% of its previous 30-day average volume of 689.40 thousand.

The stock's 50-day moving average was $61.23 at the time this article was published. Over the past fifty-two weeks, the price has risen as high as $151.8 and fallen to a low of $43.0.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.